Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quizartinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 20/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 1/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | MUSK | O15146 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | PAK3 | O75914 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quizartinib SCHEMBL72923 | 1.00 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL29435035 | 0.99 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL742377 | 0.99 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL74121 | 0.99 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL73633 | 0.97 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL3453696 | 0.96 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL72924 | 0.95 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL742748 | 0.94 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL74122 | 0.94 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL769118 | 0.94 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4498 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-224290117-U | Aviation obstruction light control circuit of split type control | Hebei Xinhai Chemical Group Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-224287543-U | Portable two-way device of punching card | Qingdao Metro Operation Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-3429570-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | ORYZON GENOMICS SA (ES) | 2026-05-20 | — | — | EP | claimed |
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731220-A2 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | Dana Farber Cancer Institute, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-4722388-A1 | PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA | Koninklijke Philips N.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| EP-3419593-B1 | ENASIDENIB FOR USE IN THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA | CELGENE CORP (US) | 2022-03-23 | — | — | EP | claimed |
| US-20220081436-A1 | SOLID FORMS OF A COMPOUND FOR MODULATING KINASES | Opna Bio SA (CH) | 2022-03-17 | — | — | US | claimed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022027237-A1 | APPLICATION OF QUIZARTINIB AS NECROPTOSIS INHIBITOR | 宜昌市第一人民医院（三峡大学人民医院） | 2022-02-10 | — | — | WO | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
| US-20220031697-A1 | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors | NOVARTIS PHARMA AG (CH) | 2022-02-03 | — | — | US | claimed |
| CN-114007671-A | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancer of epithelial tissue | 休斯敦大学体系 | 2022-02-01 | — | — | CN | claimed |
| CN-215679547-U | Commercial power current excess current alarm device | 成都市美蓝电子仪器有限公司 | 2022-01-28 | — | — | CN | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |